PRRT2 and diffuse large B-cell lymphoma: Clinical studies with PKC inhibitors in CLL have not yet been conducted, but phase 2 clinical trials are ongoing with sotrastaurin in DLBCL and with the dual PKC and AKT inhibitor enzastaurin in DLBCL, FL and mantle cell lymphoma.